Showing results (11-20 of 406) with videos related to
Sort By:
Pageof 41
Bulletin Du Cancer|October 26, 2013
[Bone targeted therapies: new agents]Claire Barth, Christophe Massard, Stéphane VignotAnnales De Pathologie|December 11, 2008
[Molecular biology and prostate cancer: evolution or revolution?]Vincent Molinié, Philippe Beuzeboc, Wafa K Mahjoub, et al.European Urology|May 20, 2014
Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted TherapiesNader Al Nakouzi, Sylvestre Le Moulec, Laurence Albigès, et al.Bulletin Du Cancer|December 8, 2011
[Metronomic chemotherapy in 2011: update and perspectives]Zineb Benbrahim, Christophe Massard, Omar El MesbahiClinical Genitourinary Cancer|January 7, 2011
Changing therapeutic paradigms in castrate-resistant prostate cancerAndrea Zivi, Christophe Massard, Johann De-BonoBulletin Du Cancer|January 24, 2013
[Prognostic factors for patients with brain metastases]Romuald Le Scodan, Christophe Massard, Georges NoëlCurrent Opinion in Oncology|April 9, 2014
Implementing precision medicine initiatives in the clinic: a new paradigm in drug developmentAntoine Hollebecque, Christophe Massard, Jean-Charles SoriaCurrent Opinion in Oncology|March 14, 2012
Vascular disrupting agents: a delicate balance between efficacy and side effectsAntoine Hollebecque, Christophe Massard, Jean-Charles SoriaCurrent Urology Reports|December 6, 2011
Targeted therapies in metastatic renal cell carcinoma: overview of the past yearMarine Gross-Goupil, Christophe Massard, Alain RavaudBulletin Du Cancer|April 21, 2012
[Management of metastatic castration-resistant prostate cancer following docetaxel]Philippe Beuzeboc, Stanislas Ropert, François Goldwasser, et al.Pageof 41